Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I Study to Assess the Safety, Cell Kinetics and Clinical Activity of Multiple Doses of CYAD-101, Administered Concurrently With the FOLFOX Treatment in Patients With Unresectable Metastatic Colorectal Cancer

Next Previous
Trial Profile

An Open-label, Phase I Study to Assess the Safety, Cell Kinetics and Clinical Activity of Multiple Doses of CYAD-101, Administered Concurrently With the FOLFOX Treatment in Patients With Unresectable Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYAD 101 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms alloSHRINK
  • Sponsors Celyad

    • Most Recent Events

    • 11 Nov 2019 According to a Celyad media release, the Company plans to expand this trial to further evaluate CYAD-101 with prior FOLFOX chemotherapy in refractory mCRC patients. Enrolment in this expansion segment is expected to begin in mid-2020.
    • 11 Nov 2019 According to a Celyad media release, additional three patients have been enrolled at dose level three (one billion cells per infusion) in this study. Total nine patients are planned in this cohort. Preliminary results from the completed dose-escalation segment of this study are expected in first half 2020.
    • 11 Nov 2019 Results presented in a Celyad media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top